Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04533165
Other study ID # 20-2015.cc
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 11, 2021
Est. completion date May 2025

Study information

Verified date June 2024
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this investigation is to establish the feasibility and initial effectiveness of a novel exercise program for rural cancer survivors in Colorado suffering from cancer related fatigue. Participation in an exercise program has regularly been shown to reduce fatigue in cancer survivors, though in-person, supervised participation has a greater effect on fatigue than home-based programs with no supervision. Access to these supervised programs are limited in rural areas, restricting the ability of rural cancer survivors to experience the fatigue-reducing benefits of exercise. The proposed program will use information on improvements in fatigue from participants in the BfitBwell Cancer Exercise Program to monitor improvements in fatigue in rural cancer survivors performing a home exercise program and trigger a telehealth session with a cancer exercise specialist to adapt the exercise prescription when improvements are less than expected. The BfitBwell Program is an established exercise program at the Anschutz Health and Wellness Center which has worked with over 600 cancer survivors and is highly effective at reducing cancer related fatigue. The goal of the program is to replicate the effects of a successful supervised exercise program in rural cancer survivors who do not have access to this type of program. This investigation will recruit 20 rural cancer survivors experiencing fatigue and assess their ability to participate in the program, as well as how well the program improves their fatigue. Interviews will be conducted with participants after the program to determine how future versions of the program could be improved. The investigators anticipate that this program will be feasible and effective, providing preliminary data to pursue a large-scale clinical trial of the program following this project's completion.


Description:

The proposed exercise program utilizes a novel reference chart system to monitor cancer-related fatigue (CRF) and trigger necessary interventions. This reference chart has been developed from CRF data collected in 173 cancer survivors participating in the BfitBwell Program, a highly effective supervised exercise program pioneered at the University of Colorado. The reference chart estimates the continuous trajectory of fatigue improvement during the three-month program. The focus of this study is to extend the benefits of an effective, supervised exercise program to rural Coloradoans via a home exercise program supported by CRF monitoring and symptom-triggered telehealth sessions. Deviations from estimated improvements in CRF will trigger telehealth sessions with a cancer exercise specialist (CES) to adapt the exercise prescription, in real time, as in a supervised program. The intent is to replicate the effects of a supervised exercise program in cancer survivors in rural areas without access to such programs. The feasibility, effectiveness, and design of the program will be assessed with two specific aims. Aim 1: Determine the feasibility and preliminary effectiveness of the proposed exercise program. Objective 1a: Assess the enrollment rate of patients able and willing to participate in the program and the adherence of patients enrolled in the program to their prescribed exercise, CRF monitoring, and telehealth session participation. Objective 1b: Assess the effect of the proposed program on CRF improvements in enrolled participants and compare this effect to that of the supervised BfitBwell exercise program. Exploratory Objective 1: Assess the feasibility of the semi-continuous remote monitoring of fatigue (ecological momentary assessment) to better tailor the program to more acute changes in CRF. Aim 2: Assess participant perspectives of barriers and facilitators to participation in the prescribed exercise and CRF monitoring. Objective 2: Gather qualitative data on barriers and facilitators to participation from all participants enrolling in the program using semi-structured interviews. This is an innovative program, being the first exercise intervention to implement real time adaptations for rural patients, with decisions anchored against a novel symptom monitoring system. Qualitative data will be collected to improve the next iteration of the program and to inform a future, large-scale clinical trial of program implementation in rural populations. The long-term goal is to develop a feasible and effective exercise program for rural cancer survivors which replicates the benefits of supervised exercise programs to which access may be restricted in rural settings. This is a prospective, single-arm pilot intervention trial. It will collect objective data on the feasibility and effectiveness of the intervention, as well as qualitative data to inform how the intervention could be improved in future iterations. The exploratory aim will collect data on "in-the-moment" fatigue that could also inform novel future versions of the intervention. This investigation will recruit adult cancer survivors treated at the University of Colorado Cancer Center (aged 18 years and over) who live in rural Colorado, have completed cancer treatment, and report moderate-to-severe CRF (> 3 on a 0-10 scale, per NCCN definition). Cancer type will be limited to the three types with the highest anticipated new cases in Colorado in 2020: breast, prostate, and lung. Only survivors who have completed medical treatment (chemotherapy and/or radiation), with curative intent, within the past 12 months, and have no additional treatment planned for the next four months, will be recruited. Rural participants will be defined as those who have greater than a 1-hour commute to the major front range cities (Denver, Fort Collins, and Colorado Springs). Participants must have home internet access and smartphones to allow participation in telehealth sessions and remote monitoring of exercise participation and fatigue. Participants with medical conditions that would impact the safety of, or participation in, an exercise program will be excluded. Twenty participants will be recruited in one year, with the goal of retaining at least 15 through the final assessment. Participants will complete assessments (baseline and final) and exercise sessions virtually. The primary outcome measure will be the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale. Other assessment items will include measures of physical fitness and function. CRF will be assessed by questionnaires every two weeks, and semi-continuously with a smartphone application. The exercise program is 12 weeks long, and includes 2 mandatory virtual exercise sessions, and up to 5 triggered virtual exercise sessions. Participants will be mailed equipment to complete the study upon enrollment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 19
Est. completion date May 2025
Est. primary completion date April 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Adult (>= 18 years) cancer survivor treated at the University of Colorado Cancer Center o A maximum age of 80 will be set as virtual exercise may become unsafe as individuals get older. - A primary cancer diagnosis of breast, prostate, or lung cancer - Current report of moderate-to-severe fatigue (> 3 on a 0-10 scale, per NCCN definition30) - Live in rural Colorado (> 1-hour commute to major front range city [Denver, Fort Collins, and Colorado Springs]) - Completed medical cancer treatment (chemotherapy and/or radiation) with curative intent within past 12 months. o No additional treatment planned for next 4 months - High-speed home internet and smartphone Exclusion Criteria: - Medical conditions that would impact the safety of, or participation in, an exercise program. This includes: - Orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries - Advanced rheumatoid arthritis - Widespread chronic pain conditions such as fibromyalgia - Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplemental oxygen - Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.

Locations

Country Name City State
United States Anschutz Health and Wellness Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver Cancer League of Colorado

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Ecological momentary assessments of fatigue 11 point fatigue intensity scale with higher scores indicating increased fatigue Semi-continuous throughout program, up to 12 weeks
Other The Feeling Scale - Pre-exercise 11 point scale of perceived affect during exercise, positive scores indicating positive affect, negative scores indicating negative affect Immediately before each exercise session
Other The Feeling Scale - Post-exercise 11 point scale of perceived affect during exercise, positive scores indicating positive affect, negative scores indicating negative affect Immediately after each exercise session
Other Rate of perceived exertion 11 point scale of perceived work/intensity during exercise. Higher scores indicate more intense workout. Immediately after every exercise session
Primary Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 12 weeks 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. Baseline (week 0), 12 weeks
Secondary Changes in Steps per day Average steps per day over a 7 day period, assessed with commercial fitness tracker Baseline (week 0), 12 weeks
Secondary Changes in Average sleep time Average sleep time per day over a 7 day period, assessed with commercial fitness tracker Baseline (week 0), 12 weeks
Secondary Changes in Single limb stance Time participant can stand on one leg, up to 30 s Baseline (week 0), 12 weeks
Secondary Changes in Gait speed Gait speed over a 4 m distance, in m/s Baseline (week 0), 12 weeks
Secondary Changes in Timed up and go Time (in s) to rise from a chair, walk 3 m, turn around, walk back to chair, and sit down Baseline (week 0), 12 weeks
Secondary Changes in 30 s Sit-to-Stand Number of times one can stand and sit from a chair in 30 s Baseline (week 0), 12 weeks
Secondary Changes Tecumseh Step Test Participants steps on and off an 8" step at a rate of 24 steps/min for 3 min. Heart rate is recorded at 30 s and 1 min after completion. Baseline (week 0), 12 weeks
Secondary Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 12 weeks Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life Baseline (week 0), 12 weeks
Secondary Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 6 month Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life Baseline (week 0), 6 months
Secondary Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 9 months Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life Baseline (week 0), 9 months
Secondary Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 15 months Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life Baseline (week 0), 15 months
Secondary Changes in Multidimensional Fatigue Inventory (MFI) at 12 weeks Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue Baseline (week 0), 12 weeks
Secondary Changes in Multidimensional Fatigue Inventory (MFI) at 6 months Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue Baseline (week 0), 6 months
Secondary Changes in Multidimensional Fatigue Inventory (MFI) at 9 months Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue Baseline (week 0), 9 months
Secondary Changes in Multidimensional Fatigue Inventory (MFI) at 15 months Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue Baseline (week 0), 15 months
Secondary Changes in Hospital Anxiety and Depression Scale (HADS) at 12 weeks Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression Baseline (week 0), 12 weeks
Secondary Changes in Hospital Anxiety and Depression Scale (HADS) at 6 months Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression Baseline (week 0), 6 months
Secondary Changes in Hospital Anxiety and Depression Scale (HADS) at 9 months Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression Baseline (week 0), 9 months
Secondary Changes in Hospital Anxiety and Depression Scale (HADS) at 15 months Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression Baseline (week 0), 15 months
Secondary Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 12 weeks Self-report of time spent in light, moderate, and vigorous physical activity in minutes. Baseline (week 0), 12 weeks
Secondary Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 6 months Self-report of time spent in light, moderate, and vigorous physical activity in minutes. Baseline (week 0), 6 months
Secondary Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 9 months Self-report of time spent in light, moderate, and vigorous physical activity in minutes. Baseline (week 0), 9 months
Secondary Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 15 months Self-report of time spent in light, moderate, and vigorous physical activity in minutes. Baseline (week 0), 15 months
Secondary Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 6 months 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. Baseline (week 0), 6 months
Secondary Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 9 months 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. Baseline (week 0), 9 months
Secondary Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 15 months 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. Baseline (week 0), 15 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients